Conjugation of Vancomycin with a Single Arginine Improves Efficacy against Mycobacteria by More Effective...

Area of Science:

• Microbiology
• Drug Discovery
• Medicinal Chemistry

Background:

• Drug-resistant bacterial infections pose a significant global health threat.
• New antimicrobial strategies are urgently needed to combat resistant pathogens.
• Vancomycin is a critical antibiotic for Gram-positive infections.

Purpose of the Study:

• To develop and evaluate a novel vancomycin-arginine conjugate (V-R) as an antimicrobial agent.
• To assess the efficacy of V-R against mycobacteria, including challenging biofilm populations.
• To explore synergistic antimicrobial combinations targeting mycobacterial cell-wall synthesis.

Main Methods:

• Synthesis and characterization of the vancomycin-arginine conjugate (V-R).
• Antimicrobial susceptibility testing against actively growing and biofilm-forming mycobacteria.
• Combination studies with ethambutol to evaluate synergistic effects.
• Mechanistic studies and molecular modeling to elucidate the mode of action.

Main Results:

• The vancomycin-arginine conjugate (V-R) demonstrated high efficacy against actively growing mycobacteria and mycobacterial biofilms.
• Combination therapy of V-R with ethambutol showed enhanced antimicrobial activity.
• Mechanistic data and molecular modeling suggest the arginine modification enhances activity against mycobacterial peptidoglycan synthesis.

Conclusions:

• The vancomycin-arginine conjugate (V-R) represents a promising new antimicrobial agent for mycobacterial infections.
• Targeting distinct cell-wall synthesis pathways through synergistic combinations offers a potent strategy against mycobacteria.
• The arginine modification confers specificity for mycobacterial cell-wall chemistry, distinct from Gram-positive pathogens.